Control-Based Imputation and Delta-Adjustment Stress Test for Missing Data Analysis in Longitudinal Clinical Trials

被引:15
作者
Liu, G. Frank [1 ]
Pang, Lei [1 ]
机构
[1] Merck Res Labs, 351 N Sumneytown Pike,UG1CD 44, N Wales, PA 19454 USA
来源
STATISTICS IN BIOPHARMACEUTICAL RESEARCH | 2017年 / 9卷 / 02期
关键词
Longitudinal clinical trial; Missing data; Multiple imputation; Sensitivity analysis; Tipping point analysis; MULTIPLE-IMPUTATION; ACCESSIBLE ASSUMPTIONS; PROTOCOL DEVIATION; INFERENCE; FRAMEWORK; RELEVANT;
D O I
10.1080/19466315.2016.1256830
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Sensitivity analyses using multiple imputation (MI) provide a flexible approach to assess the impact of missing data on clinical trial results. An approach that imputes missing data in the test drug group using a model built from the control group has gained attention in recent research. This control-based imputation (CBI) approach typically provides a conservative point estimate for treatment difference. However, the combined variance using Rubin's rule may over-estimate the variability. In this article, we investigate the statistical properties for some specific CBI methods, and show the relationship between CBI and delta-adjustment tipping point analysis. This relationship helps us to understand and interpret the results from CBI using MI with Rubin's rule. In addition, we propose a new sensitivity measure for assessing the robustness of the result obtained under a missing at random (MAR) assumption. Results from simulation studies and applications to longitudinal clinical trial datasets are presented as illustration.
引用
收藏
页码:186 / 194
页数:9
相关论文
共 22 条
[1]  
[Anonymous], 2015, STAT MED, V35, P2876
[2]  
[Anonymous], 2010, Guideline on missing data in confirmatory clinical trials
[3]  
[Anonymous], 2010, PREV TREATM MISS DAT
[4]   A Multiple-Imputation-Based Approach to Sensitivity Analyses and Effectiveness Assessments in Longitudinal Clinical Trials [J].
Ayele, Birhanu Teshome ;
Lipkovich, Ilya ;
Molenberghs, Geert ;
Mallinckrodt, Craig H. .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (02) :211-228
[5]  
Carpenter J, 2007, Missing data in randomised controlled trials: a practical guide
[6]   Response to Comments by Seaman et al. on "Analysis of Longitudinal Trials With Protocol Deviation: A Framework for Relevant, Accessible Assumptions, and Inference via Multiple Imputation," Journal of Biopharmaceutical Statistics 23:1352-1371 [J].
Carpenter, J. R. ;
Roger, J. H. ;
Cro, S. ;
Kenward, M. G. .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (06) :1363-1369
[7]   ANALYSIS OF LONGITUDINAL TRIALS WITH PROTOCOL DEVIATION: A FRAMEWORK FOR RELEVANT, ACCESSIBLE ASSUMPTIONS, AND INFERENCE VIA MULTIPLE IMPUTATION [J].
Carpenter, James R. ;
Roger, James H. ;
Kenward, Michael G. .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2013, 23 (06) :1352-1371
[8]   Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder [J].
Keller, M ;
Montgomery, S ;
Ball, W ;
Morrison, M ;
Snavely, D ;
Liu, GH ;
Hargreaves, R ;
Hietala, J ;
Lines, C ;
Beebe, K ;
Reines, S .
BIOLOGICAL PSYCHIATRY, 2006, 59 (03) :216-223
[9]   A regulatory perspective on missing data in the aftermath of the NRC report [J].
LaVange, Lisa M. ;
Permutt, Thomas .
STATISTICS IN MEDICINE, 2016, 35 (17) :2853-2864
[10]   Choosing Appropriate Estimands in Clinical Trials [J].
Leuchs, Ann-Kristin ;
Zinserling, Joerg ;
Brandt, Andreas ;
Wirtz, Dorothee ;
Benda, Norbert .
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (04) :584-592